To investigate the role of cytomegalovirus (CMV) infection in the pathogenesis of peripheral neuropathy in children with acquired immunodeficiency syndrome (AIDS) a crosssectional descriptive study was conducted on a sample of nine children. Plasma samples were tested for CMV DNA by two polymerase chain reaction assays (sensitivity limits of 400 and 10 copies/mls) respectively. While all nine were CMV seropositive all were negative for viremia in both assays. CMV would appear not to be involved in children with AIDS-associated sensory neuropathies. (J Pediatr Neurol 2004; 2(4): 219-223).
Introduction
Serologic and virus isolation studies have documented an extremely high prevalence of cytomegalovirus (CMV) infection in most human immunodeficiency virus (HIV)-infected patient populations. Autopsy studies have shown CMV to be the commonest opportunistic infection in acquired immunodeficiency syndrome (AIDS) patients (1) . Neurological disorders associated with CMV infection in patients with AIDS include the involvement of both the peripheral and central nervous system, with the former presenting with a range of clinical findings which include polyradiculitis, multifocal neuritis and symmetrical peripheral neuropathies (2) .
Peripheral neuropathy has been shown to occur in one third of adults and children with AIDS (3, 4) and has been associated with multiple factors. It may be related to HIV infection itself, to a range of drugs, to the nutritional status of the patients and to other infectious agents.
Several reports have indicated an etiological role for CMV in the pathogenesis of peripheral neuropathy, and of specifically HIV-CMV coinfection of the peripheral nerves has been described (5) (6) (7) (8) (9) . Autopsy studies of patients with AIDS and peripheral neuropathies have shown the eventual presence of cytomegalic inclusions in the spinal cord (7) and CMV mRNA was reported to be present in macrophages in the dorsal root ganglia (10) . In this study we have investigated the role of HIV-CMV co-infection in children with AIDS and peripheral neuropathy.
Materials and Methods
A cross-sectional descriptive study was conducted on a sample of children with AIDS and peripheral neuropathy, which was selected from a cohort of the pediatric HIV out-patient clinic at the Federal University of Rio de Janeiro. The clinical details of the patients have been previously published, and 9 of 13 patients, included in the previous report (3) agreed to participate. The Institutional Review Board approved this study, and informed consent was obtained from all patients.
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Absence of cytomegalovirus infection in children with acquired immunodeficiency syndrome and distal sensory polyneuropathy
The patient was considered to have peripheral neuropathy if presenting simultaneously at least one symptom (distal pain, paresthesia, hypoesthesia, or weakness) and one sign (amyotrophy, hypotonia, weakness, diminished deep tendon reflexes, hypoesthesia, or postural hypotension). They were then classified as HIV-1-associated predominantly sensory polyneuropathy according to the case definitions for neurologic manifestations of HIV-1 infection elaborated by the Working Group of the American Academy of Neurology AIDS task Force (11) . Cornblath criteria were applied on nerve conduction studies results to classify those as either axonal or demyelinating (12) .
Polymerase chain reaction (PCR) for CMV DNA detection
Plasma samples were processed at the National Virus Reference Laboratory (NVRL), University College Dublin, Ireland. Standard procedures were employed which included physical separation of the nucleic acid extration, PCR preparation and PCR product analysis steps to prevent crosscontamination. Two assays were employed (A) "In house" nested CMV PCR. Plasma was separated from EDTA-treated whole blood and samples were kept frozen until assayed. Nucleic acid was extracted from 0.2 ml of each plasma sample using the Qiagen DNA blood kit according to the manufacturer's protocol. In the PCR a region of the immediate early gene region was amplified with a final product size of 263bp. Primer sequences were for the first round of PCR were 5' AGC CTT CCC TAA GAC CAC C 3' and 5' Bio-CCT CTT CCT CAT CTG ACT CC 3' and for the second round 5' GGT GCT CAC GCA CAT TGA TC 3' and 5' Bio-AGA CCT TCA TGC AGA TCT CC 3'. The amplification reaction mixture contained 0.5 μM of each primer (Promega, Madison, WI), 10 μl of a buffer solution at 8.5 pH (Perkin Elmer Cetus, Norwalk, CT), which includes 1.25 mM of MgCl2, 100 mM of each dNTP in a mix (Promega, Madison, WI), and 1.5 U of Taq polymerase (Promega, Madison, WI) in a total volume of 40 μl. The product of the first amplification step (5μl) was amplified in a reaction mixture containing 0.5 μM of each second primer (Promega, Madison, WI), 5 μl of a buffer at 8.5 pH (Perkin Elmer Cetus, Norwalk, CT), 100 mM of each dNTP in a mix (Promega, Madison, WI), and 1. An automated gene amplification and detection system was used for DNA amplification, and the amount of PCR product present was compared to that of an internal standard co-amplified in the same reaction with the same primer set. Results were calculated as DNA copies per milliliter of plasma. The primers used were specific for the CMV polymerase gene. The test is designed with an internal quantitation standard (QS) that was constructed with the same primer sequence as the target DNA but with different intervening sequences. The unique probe sequence allows for the differentiation of QS DNA and target DNA. To ensure an equivalent amplification efficiency, the QS is the same size and has a similar G+C content as the CMV target region. The QS is added at a know concentration during specimen processing so that extraction and recovery of DNA, in addition to amplification and detection, can be monitored.
Results
Nine out of 13 children with documented HIV-1-associated sensory neuropathy described in a previous study (3) agreed to participate in this investigation. All had at least one complaint related to distal peripheral neuropathy and had at least one sign of distal symmetric peripheral nerve involvement. Clinical data of the patients are summarized in Table 1 . The peripheral neuropathy, according to the nerve conduction studies done in five children, was mainly axonal in nature. The sural nerve had low amplitude and small alterations in conduction velocities or latencies. Absence of F response in peroneal nerve was also found. DNA plasma samples were analyzed using two quantitative PCR assays, a commercial assay which had a sensitivity limit of 400 copies/ml and an "in house" method, with a sensitivity 10 copies/ml respectively. All nine samples were found to be negative in both assays.
Discussion
Contrary to our expectations, this study failed to suggest a role for CMV infection in children with AIDS and peripheral neuropathy, regarding CMV viremia. Of note all children had previous
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A P de Q C Araujo et al Absence of CMV in pediatric AIDS neuropathyexposure to CMV, as all were seropositive. Peripheral neuropathy has emerged as the most common neurological complications occurring in HIV infection. Pathologic evidence for a role of CMV in peripheral neuropathy associated with AIDS was originally presented in 1984 (13) , and subsequently cytomegalic inclusions were clearly documented in patients with peripheral neuropathy (9, 14) . Those were either progressive polyneuropathy or mononeuropathy multiplex cases. In addition CMV blood antigenemia was demonstrated in 10 (76.9%) out of 13 HIV-infected patients with painful peripheral neuropathy, which is 10 times more frequent than that in individuals without this syndrome (15) .
None of our patients had the classical clinical picture of a progressive polyneuropathy, a rapidly progressive painful radiculopathy with sphincter disturbances and paraparesis. We could have children with mononeuropathy multiplex in this series, distinguished by an asymmetric sensory motor neuropathy affecting both upper and lower extremities with associated pain and variable progression. Nevertheless, the clinical findings were never asymmetric. Unfortunately, we were not able to have nerve conduction studies in four of them. The clinical features of those patients could be better attributed to an axonal sensory neuropathy. This neuropathy is a frequent complication in the course of HIV infection. It causes pain, paresthesias and burning sensations and/or numbness in the feet, which sometimes occurs in the hands as well. Neurological examination reveals sensory deficits in a stocking and glove distribution and depressed or absent ankle reflexes, without severe paresis. The cause of the sensory neuropathy is unknown. Either the HIV infection or certain other infections, for example cytomegalovirus, may play a role in the pathogenesis (15) .
The reason for the absence of CMV viremia in our population is unclear. One possibility may relate the temporal relationship of each infection. It has been reported that in the experimental co-infection of rhesus macaques with rhesus cytomegalovirus (RhCMV) and simian immunodeficiency virus (SIV) the order of those infections might be important role in the clinical outcome. When RhCMV preceded SIV inoculation, animals rarely exhibited RhCMV DNA in plasma, had low copy numbers of RhCMV DNA in most tissues, and did not develop early onset of simian AIDS or activated RhCMV (16) . In our study all patients were Brazilian children, vertically infected with HIV, and who could have acquired their CMV infection in utero, prior to HIV infection. Although it has been considered that perinatal infections are much more prevalent than congenital CMV infections (17), recent evidence have been focusing on earlier transmission (18) (19) (20) (21) .
Another likely possibility is that the HIVassociated sensory neuropathies in children simply might not be related to CMV infection. The presence of CMV inclusions reported in previous cases (9, 13, 14) were all in adult cases. Furthermore, all the reports on the association of CMV and HIV with peripheral neuropathies were prior to the introduction highly active antiretroviral therapy and the association of those two infections may have changed as a consequence of such treatment. Indeed, highly active antiretroviral therapy has decreased the overall incidence of CMV disease in AIDS (22) .
Finally, it is important to note that we restricted our study to a specific and small group of children with AIDS. It is possible that criteria used to select those patients might have selected individuals with confounding factors for a lower risk of CMV-HIV co infection. However, our data does not support a role for CMV infection in the neurological disease observed in this pediatric HIV infected population.
